Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.

about

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.

Item

http://www.wikidata.org/entity/Q50864223

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Increased SHISA3 expression ch ...... nts sensitive to lenalidomide.

@en

Increased SHISA3 expression ch ...... nts sensitive to lenalidomide.

@nl

type

Item

label

Increased SHISA3 expression ch ...... nts sensitive to lenalidomide.

@en

Increased SHISA3 expression ch ...... nts sensitive to lenalidomide.

@nl

prefLabel

Increased SHISA3 expression ch ...... nts sensitive to lenalidomide.

@en

Increased SHISA3 expression ch ...... nts sensitive to lenalidomide.

@nl

P1476

Increased SHISA3 expression ch ...... nts sensitive to lenalidomide.

@en

P2093

Antonio Cuneo

http://www.w3.org/2001/XMLSchema#string

Daniele Vallisa

http://www.w3.org/2001/XMLSchema#string

Davide Rossi

http://www.w3.org/2001/XMLSchema#string

Francesco Forconi

http://www.w3.org/2001/XMLSchema#string

Gian Matteo Rigolin

http://www.w3.org/2001/XMLSchema#string

Gianluca Gaidano

http://www.w3.org/2001/XMLSchema#string

Giulia Debbia

http://www.w3.org/2001/XMLSchema#string

Lara Rizzotto

http://www.w3.org/2001/XMLSchema#string

Luca Laurenti

http://www.w3.org/2001/XMLSchema#string

Rita Santachiara

http://www.w3.org/2001/XMLSchema#string

P2860

Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53

P304

423-433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1339872

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mario Luppi

Jenny Bulgarelli

Giuseppe Alberto Palumbo

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28639485

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte